Frederic Chereau, LogicBio Therapeutics CEO

Months lat­er, Log­icBio ex­its FDA clin­i­cal hold for gene edit­ing drug but won't restart tri­al un­til next quar­ter

Log­icBio Ther­a­peu­tics has re­ceived some good news this morn­ing as the FDA has lift­ed a three-month clin­i­cal hold on one of the com­pa­ny’s pri­ma­ry tri­als for a po­ten­tial gene edit­ing drug, but the tri­al isn’t ex­pect­ed to re­sume un­til next quar­ter.

En­roll­ment in the Phase I/II tri­al, dubbed SUN­RISE, for Log­icBio’s gene edit­ing ther­a­py LB-001 will be al­lowed to re­sume. The tri­al is fo­cused on pe­di­atric pa­tients with methyl­malonic acidemia, or MMA, an in­her­it­ed dis­or­der in which the body is un­able to process cer­tain pro­teins and lipids prop­er­ly.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters